Fig. 2.

Low-density lipoprotein cholesterol (LDL-C) change from baseline to week 12 by underlying genetic abnormality in the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (TAUSSIG) study with evolocumab added to conventional drug therapy in patients with homozygous familial hypercholesterolemia. Mean change in LDL-C is shown in parentheses after each genetic abnormality category. Adapted from Raal et al., with permission from Elsevier [63]. LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; GoF, gain-of-function; ARH, autosomal recessive hypercholesterolemia. ^aApheresis patient; ^bPatient missed apheresis before the week 12 blood draw due to a snowstorm; ^cWeek 12 immediately after vacation, dietary indiscretion suspected.